Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer
American Journal of Physiology-Cell Physiology · 01.09.2025 · 329 (3) · C699-C717
DOI: 10.1152/ajpcell.00412.2025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.09.2025. Verfasst von Ralph A de Groot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Drug Resistance, Multiple, ATP-Binding Cassette Transporters. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 194 Literaturangaben. Gefördert von: EC | HORIZON EUROPE Framework Programme (Horizon Europe), NWO (Netherlands Organization for Scientific Research.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with multidrug resistance (MDR) significantly limiting the effectiveness of chemotherapy. A major contributor to MDR is the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein ( ABCB1/P-gp), breast cancer resistance protein ( ABCG2/BCRP), and multidrug resistance-associated proteins ( ABCC/MRPs). These transporters actively efflux chemotherapeutic agents, reducing their intracellular drug accumulation and efficacy. This review outlines both clinical and emerging strategies that aim to overcome ABC transporter-mediated resistance in CRC. Herein, we detail the functional role of ABC transporters in CRC, followed by clinically tested approaches, such as pharmacological inhibitors, natural compound inhibitors, as well as nanoparticle-based drug delivery systems, that have been explored to circumvent resistance. In addition, we discuss emerging preclinical approaches, including CRISPR/Cas9 gene-editing, RNA interference, epigenetic modulators, and gut microbiome-targeted interventions, that hold promise for future therapeutic translation. By integrating clinically validated and experimental strategies, this review highlights the importance of a multimodal approach to effectively circumvent MDR in CRC and optimize personalized treatment strategies to improve clinical outcomes. ABC transporters; chemoresistance; colorectal cancer; multidrug resistance; therapies
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
ORCID-Profile: Ralph A de Groot, Quentin Faucher, Silvia M Mihăilă, Rosalinde Masereeuw
Förderung
- EC | HORIZON EUROPE Framework Programme (Horizon Europe)
- NWO (Netherlands Organization for Scientific Research
Zitieren
APA
de Groot, R. A., Reedijk, D., Faucher, Q., Mihăilă, S. M., & Masereeuw, R. (2025). Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer. American Journal of Physiology-Cell Physiology, 329(3), C699-C717. https://doi.org/10.1152/ajpcell.00412.2025
Vancouver
de Groot RA, Reedijk D, Faucher Q, Mihăilă SM, Masereeuw R. Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer. American Journal of Physiology-Cell Physiology. 2025;329(3):C699-C717. doi:10.1152/ajpcell.00412.2025
BibTeX
@article{deGroot2025,
author = {de Groot, Ralph A and Reedijk, Daan and Faucher, Quentin and Mihăilă, Silvia M and Masereeuw, Rosalinde},
title = {Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer},
journal = {American Journal of Physiology-Cell Physiology},
year = {2025},
volume = {329},
number = {3},
pages = {C699--C717},
doi = {10.1152/ajpcell.00412.2025}
}
EUVIMED